Maegim한국어

알리코제약

260660KOSDAQSector: Pharma & Biotech
₩2,305 0.66%Market cap ₩35.3BAs of Jul 21, 2026 close · updated once daily
B
Grade B52.8 ptsTop 48% of 2,523 stocks
Financial strength
38.3
Growth momentum
52.2
Price attractiveness
69.7

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

38.3
How much debt does it carry relative to equity?
Debt-to-equity ratio
119.7%
Below median · Top 82.3% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
112.1%
Below median · Top 72.6% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
0.5%
Above median · Top 47.5% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
-0.8%
Above median · Top 44.5% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original

2

Growth momentum

52.2
How much did revenue grow in a year?
Revenue growth (YoY)
5.7%
Below median · Top 54.6% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
6.3%
Above median · Top 45.9% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
119.2%
Above median · Top 11.4% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-90.0%
Below median · Top 79.3% in sector
Sector median 3.5%

Source filing: annual report (separate) — view original

3

Price attractiveness

69.7
Is the price expensive relative to earnings?
P/E (price-to-earnings)
Loss-making (P/E not computable)
Below median · Top 50.6% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.45x
Above median · Top 10% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15